Aptevo Therapeutics Inc. (APVO) — Current Report

AI-Powered SEC Filing Analysis

Latest Current Report Filed: 2026-05-06

Key Insights

Aptevo announced positive clinical results from its RAINIER Phase 1b trial for mipletamig in frontline AML, demonstrating progress in a high-value indication with significant commercial potential if efficacy is sustained.
The company is on track to complete dose-optimization and select the recommended Phase 2 dose in 2026, indicating a clear near-term catalyst and advancement toward pivotal trial stage.
Phase 2 trial design will maintain the same combination approach (mipletamig with venetoclax and azacitidine), suggesting the current regimen is tolerable and potentially effective enough to advance without fundamental changes.

Want the newest filings?

This analysis covers the filing from 2026-05-06. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Earlier Current Report filings

Filed: 2026-03-26

Aptevo Therapeutics reported its financial results for the period ended December 31, 2025, indicating the company's continued operations and financial performance.
The filing does not mention any material events or changes, suggesting a relatively stable quarter for the company.
Investors should monitor the company's future financial performance and any updates on its product pipeline or strategic initiatives.

Filed: 2026-03-11

Aptevo Therapeutics announced new interim data for its drug mipletamig in combination with venetoclax and azacitidine for treating newly diagnosed acute myeloid leukemia (AML) patients.
The new data could potentially be a positive development for the company's pipeline and future commercial prospects in the AML treatment market.
Investors should monitor further updates on the progress of this drug candidate and its potential regulatory and commercial implications.

Filed: 2026-01-09

Aptevo Therapeutics entered into a $60 million standby equity purchase agreement with Yorkville, which provides the company access to additional capital to fund operations.
The agreement includes an exchange cap of 199,466 shares (19.99% of outstanding shares) unless stockholder approval is obtained or the stock price meets certain conditions.
Yorkville's obligation to purchase shares is subject to the effectiveness of a registration statement covering the shares to be issued, among other conditions.

Other reports for Aptevo Therapeutics Inc.

Annual Report

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.